AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses
Frontiers in Oncology · 07.01.2025 · 14
DOI: 10.3389/fonc.2024.1509362 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 07.01.2025. Verfasst von Saram Abbas und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Non-muscle-invasive Bladder Cancer (NMIBC) is notorious for its high recurrence rate of 70-80%, imposing a significant human burden and making it one of the costliest cancers to manage. Current prediction tools for NMIBC recurrence rely on scoring systems that often overestimate risk and lack accuracy. Machine learning (ML) and artificial intelligence (AI) are transforming oncological urology by leveraging molecular and clinical data to enhance predictive precision.
Methods
This comprehensive review critically examines ML-based frameworks for predicting NMIBC recurrence. A systematic literature search was conducted, focusing on the statistical robustness and algorithmic efficacy of studies. These were categorised by data modalities (e.g., radiomics, clinical, histopathological, genomic) and types of ML models, such as neural networks, deep learning, and random forests. Each study was analysed for strengths, weaknesses, performance metrics, and limitations, with emphasis on generalisability, interpretability, and cost-effectiveness.
Results
ML algorithms demonstrate significant potential, with neural networks achieving accuracies of 65–97.5%, particularly with multi-modal datasets, and support vector machines averaging around 75%. Models combining multiple data types consistently outperformed single-modality approaches. However, challenges include limited generalisability due to small datasets and the "black-box" nature of advanced models. Efforts to enhance explainability, such as SHapley Additive ExPlanations (SHAP), show promise but require refinement for clinical use.
Conclusion
This review illuminates the nuances, complexities and contexts that influence the real-world advancement and adoption of these AI-driven techniques in precision oncology. It equips researchers with a deeper understanding of the intricacies of the ML algorithms employed. Actionable insights are provided for refining algorithms, optimising multimodal data utilisation, and bridging the gap between predictive accuracy and clinical utility. This rigorous analysis serves as a roadmap to advance real-world AI applications in oncological care, highlighting the collaborative efforts and robust datasets necessary to translate these advancements into tangible benefits for patient management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Engineering, Newcastle University, Newcastle Upon Tyne, United Kingdom.
- Department of Urology, Freeman Hospital, Newcastle upon Tyne, United Kingdom.
- Division of Surgery, Imperial College London, London, United Kingdom.
- Centre for Cancer, Newcastle University, Newcastle upon Tyne, United Kingdom.
Zitieren
APA
Abbas, S., Shafik, R., Soomro, N., Heer, R., & Adhikari, K. (2025). AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses. Frontiers in Oncology, 14. https://doi.org/10.3389/fonc.2024.1509362
Vancouver
Abbas S, Shafik R, Soomro N, Heer R, Adhikari K. AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses. Frontiers in Oncology. 2025;14. doi:10.3389/fonc.2024.1509362
BibTeX
@article{Abbas2025,
author = {Abbas, Saram and Shafik, Rishad and Soomro, Naeem and Heer, Rakesh and Adhikari, Kabita},
title = {AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses},
journal = {Frontiers in Oncology},
year = {2025},
volume = {14},
doi = {10.3389/fonc.2024.1509362}
}
EUVIMED